Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Klabunde

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
IEEE Transactions on Bio-Medical Engineering|February 9, 2019
Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI TherapiesRoberto Visentin, Michele Schiavon, Clemens Giegerich, et al.
IEEE Transactions on Bio-Medical Engineering|June 1, 2019
Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 DiabetesMichele Schiavon, Roberto Visentin, Clemens Giegerich, et al.
Diabetes, Obesity & Metabolism|April 6, 2021
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutideMichele Schiavon, Roberto Visentin, Britta Göbel, et al.
Diabetes, Obesity & Metabolism|December 7, 2019
Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetesRoberto Visentin, Michele Schiavon, Britta Göbel, et al.
Diabetes Technology & Therapeutics|March 4, 2020
<i>In Silico</i> Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 DiabetesMichele Schiavon, Roberto Visentin, Clemens Giegerich, et al.
Bioinformatics (Oxford, England)|November 7, 2012
DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression dataClare Pacini, Francesco Iorio, Emanuel Gonçalves, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 2003
Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assayAlexandre Brkovic, Almut Hattenberger, Evi Kostenis, et al.
Biochemistry|April 1, 2008
Thermodynamic characterization of allosteric glycogen phosphorylase inhibitorsOliver Anderka, Petra Loenze, Thomas Klabunde, et al.
Nature Communications|November 15, 2016
Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretionFrancesca Sacco, Sean J Humphrey, Jürgen Cox, et al.
The Journal of Biological Chemistry|March 30, 2002
Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferiChristoph Eicken, Vivek Sharma, Thomas Klabunde, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
IEEE Transactions on Bio-Medical Engineering|February 9, 2019
Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI TherapiesRoberto Visentin, Michele Schiavon, Clemens Giegerich, et al.
IEEE Transactions on Bio-Medical Engineering|June 1, 2019
Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 DiabetesMichele Schiavon, Roberto Visentin, Clemens Giegerich, et al.
Diabetes, Obesity & Metabolism|April 6, 2021
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutideMichele Schiavon, Roberto Visentin, Britta Göbel, et al.
Diabetes, Obesity & Metabolism|December 7, 2019
Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetesRoberto Visentin, Michele Schiavon, Britta Göbel, et al.
Diabetes Technology & Therapeutics|March 4, 2020
<i>In Silico</i> Head-to-Head Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL in Type 1 DiabetesMichele Schiavon, Roberto Visentin, Clemens Giegerich, et al.
Bioinformatics (Oxford, England)|November 7, 2012
DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression dataClare Pacini, Francesco Iorio, Emanuel Gonçalves, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 17, 2003
Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assayAlexandre Brkovic, Almut Hattenberger, Evi Kostenis, et al.
Biochemistry|April 1, 2008
Thermodynamic characterization of allosteric glycogen phosphorylase inhibitorsOliver Anderka, Petra Loenze, Thomas Klabunde, et al.
Nature Communications|November 15, 2016
Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretionFrancesca Sacco, Sean J Humphrey, Jürgen Cox, et al.
The Journal of Biological Chemistry|March 30, 2002
Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferiChristoph Eicken, Vivek Sharma, Thomas Klabunde, et al.
Pageof 3